Valiant Navion™ VNMF3131C229TURecalls & reported problems
Medtronic, Inc. · STENT GRAFT VNMF3131C229TU VAL NAV FF · Class 3 · Implant
All models of Valiant Navion (137)
Data updated Oct 18, 2026 from official FDA records · Editorial policy
- Adverse event reports
- 1
- Deaths reported
- 1
- Injuries reported
- 0
- Recalls naming it
- 0
Summary
The FDA's MAUDE database contains 1 adverse event report that list this exact device (DI 00763000100612), received between Dec 13, 2019 and Dec 13, 2019 — classified as 1 death.
Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 18, 2026.
Most reported problems
Device problems
- Adverse Event Without Identified Device or Use Problem1
Patient problems
- Death1
- Dyspnea1
Recent adverse event reports
The 1 most recent of 1 reports, in the reporter's own words as published by the FDA.
DeathDec 13, 2019Adverse Event Without Identified Device or Use Problem; Adverse Event Without Identified Device or Use Problem
A VALIANT NAVION STENT GRAFT SYSTEM WAS IMPLANTED IN A PATIENT FOR THE ENDOVASCULAR TREATMENT OF A 200MM DIAMETER THORACIC AORTIC DISSECTION. IT WAS REPORTED THAT THE PATIENT PRESENTED WITH ABDOMINAL PAIN AND A TYPE A DISSECTION WHICH EXTENDED TO THE DESCENDING THORACIC AORTA WAS DIAGNOSED. THE PATIENT WAS PREPPED FOR REPAIR AND DURING CT SCAN, IT WAS NOTED THAT THE VISCERAL VESSELS WERE NOT PATENT. IT WAS DECIDED TO PLACE A STENT GRAFT IN THE DESCENDING AORTA TO RE-ESTABLISH FLOW TO THE VISCERAL VESSELSAND IVUS WAS USED TO OBTAIN THE TRUE LUMEN. THE VALIANT NAVION WAS PLACED DISTAL TO THE SUBCLAVIAN ARTERY AND POST ANGIOGRAM STILL SHOWED NO FLOW TO THE VISCERAL VESSELS. STENTS WERE THEN PLACED IN THE CELIAC AND SMA TO SUCCESSFULLY RE-ESTABLISH FLOW. LACTATE LEVELS WERE ELEVATED POST-OP BUT BEGAN TO DECREASE TWO DAYS LATER AND SO THE PATIENT WAS EXTUBATED AND SEEMED ALERT AND ORIENTATED. THE NEXT DAY, THE PATIENT BECAME SHORT OF BREATH WHILE SITTING AND DIED. THE PHYSICIAN SAID THAT THE ASCENDING AORTA HAD RUPTURED AND THAT IT HAD BEEN PLANNED TO REPAIR THIS THE NEXT DAY AFTER THE PATIENT DIED. AS PER THE PHYSICIAN, THE CAUSE OF THE EVENT WAS ANATOMY RELATED DUE TO THE COMPLEX THOR
Patient problems: Death; Dyspnea
MAUDE report 9465604 ↗
Other SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT devices
- Endurant® IIs ESBF2814C103EMedtronic, Inc. · SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT2 recalls34 deaths254 reports
- Endurant® IIs ESBF3214C103EMedtronic, Inc. · SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT2 recalls19 deaths173 reports
- Endurant® IIs ESBF3614C103EMedtronic, Inc. · SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT1 recall37 deaths214 reports
- Endurant® IIs ESBF2514C103EMedtronic, Inc. · SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT2 recalls18 deaths136 reports
- Endurant® IIs ESBF2314C103EMedtronic, Inc. · SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT2 recalls9 deaths60 reports
- RelayPro Thoracic Stent-Graft System 28-N4-34-154-34UBolton Medical Inc. · System, Endovascular Graft, Aortic Aneurysm Treatment3 recalls7 reports
- Vela Proximal Endograft System A34-34/C100-O20 VEndologix LLC · System, Endovascular Graft, Aortic Aneurysm Treatment3 deaths152 reports
- Endurant® II ETCF2828C49EMedtronic, Inc. · SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT2 recalls7 deaths44 reports
Sources and updates
- Device record: FDA GUDID, file dated Oct 13, 2026 · View this device in AccessGUDID ↗
- Adverse event reports: FDA MAUDE, file dated Oct 14, 2026 · each report above links to its original FDA record
- Recalls: FDA Medical Device Recalls, file dated Oct 16, 2026
- Page last rebuilt: Oct 18, 2026. Data downloaded through openFDA, which notes it is not validated for clinical or regulatory use.
How reports and recalls are matched · Editorial policy · Report an error on this page